Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy

Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) provide dramatic response to patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, the use of neoadjuvant therapy with EGFR-TKIs in EGFR-mutant NSCLC remains controversial, especially in pulmonar...

Full description

Bibliographic Details
Main Authors: Xiguang Liu, Yating Zheng, Shijie Mai, Yu Tong, Lili Yang, Mengli Huang, Ruijun Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
pulmonary sarcomatoid carcinoma
osimertinib
chemotherapy
neoadjuvant
EGFR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1033322/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1033322/full

Similar Items